Sibrotuzumab
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP) . Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) [1].
Product Specifications
CAS Number
216669-97-5
Product Name Alternative
BIBH 1; Anti-Human FAP Recombinant Antibody
UNSPSC
12352203
Target
FAP
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sibrotuzumab.html
Purity
99.05
Solubility
10 mM in DMSO
Smiles
[Sibrotuzumab]
Molecular Weight
(148.66 kDa)
References & Citations
[1]Scott AM, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9 (5) :1639-47.|[2]Kobayashi T, et al., Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts Using a Humanized Anti-Fibroblast Activation Protein Antibody. Mol Cancer Ther. 2024 Jul 2;23 (7) :1031-1042.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040676-500 1x 500 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942216-500 1x 500 µL
CD50 / ICAM3 (CG106), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681081-500 1x 500 µL
CD45RO (190-2F2.5), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details